Price Vision Group in Indianapolis is the vision center with one of the most extensive experiences in corneal cross-linking (CXL). Currently, cross-linking is the only FDA approved treatment for halting the progression of keratoconus. Dr. Francis Price is one of the most experienced surgeons at performing cross-linking in the United States and contributed to the FDA approval of cross-linking and served as an investigator in the original USA clinical trials in 2008. As a result of these studies, the FDA determined that cross linking is a safe and effective treatment for keratoconus. Price Vision Group has participated in both company-sponsored and their own physician-sponsored studies of different cross-linking techniques and evaluating ways to provide better outcomes for their patients.
The cross-linking procedure involves the saturation of the cornea with a riboflavin (vitamin B2) solution administered through eye drops. A UVA light is then used to strengthen and stabilize the front layers of the cornea. Typically, patients only require one treatment procedure.
For more information and to find out if you may be a candidate, please contact our office at (800) 317-3937 to schedule an appointment for an evaluation. You can also CLICK HERE for a brochure from the Cornea Research Foundation of America with more information about keratoconus and cross-linking. Please note that this brochure discusses the research study on cross-linking conducted jointly with the Price Vision Group, but the study has ended now that the procedure has been approved by the US Food and Drug Administration in April, 2016. Despite the FDA approval, corneal cross-linking is currently still considered investigational and not covered by most medical insurance companies.